
The SCIENCE trial aimed to investigate whether a single treatment with direct intramyocardial injections of adipose tissue-derived mesenchymal stromal cells (CSCC_ASCs) was safe and improved the cardiac function in patients with chronic ischemic heart failure with reduced ejection fraction (HFrEF). The treatment was safe without any drug‐related severe adverse events or difference in cardiac-related adverse events during a 3‐years follow‐up period. There were no significant differences between the groups during follow-up in LVESV, nor in secondary endpoints left ventricular end‐diastolic volume and LVEF. The NYHA classification improved slightly within the first year in both groups without any difference between groups. There were no changes in the 6‐Minute Walk Test, NT‐ProBNP, CRP or quality‐of‐life in any of the two groups in the first year.
Like
Save
Share